ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

MRK Merck and Co Inc

131.15
0.43 (0.33%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Merck and Co Inc MRK NYSE 普通株式
  前日比 前日比 % 現在値 時刻
0.43 0.33% 131.15 08:26:37
始値 安値 高値 終値 前日終値
130.13 130.13 131.91 131.20 130.72
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2605:40IHMARKETNEWSU.S. Stocks Climb Well Off Worst Levels But Close Mostly..
2024/4/2522:09IHMARKETNEWSFutures Pointing To Sharply Lower Open On Wall Street
2024/4/2520:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
2024/4/2519:30BWMerck Announces First-Quarter 2024 Financial Results
2024/4/1920:04PRNCAHealth Canada Approves KEYTRUDA® as a first-line treatment..
2024/4/1020:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
2024/4/0419:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
2024/4/0321:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
2024/4/0119:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
2024/3/2819:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
2024/3/2719:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
2024/3/2707:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
2024/3/2119:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
2024/3/1922:00BWMerck Announces Positive Data on V116, an Investigational,..
2024/3/1605:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
2024/3/1519:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
2024/3/1316:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
2024/3/1121:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
2024/3/0700:25BWGilead and Merck Announce Phase 2 Data Showing an..
2024/3/0523:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
2024/3/0520:45BWMerck to Participate in the Barclays 26th Annual Global..
2024/3/0420:45BWMerck to Participate in the Leerink Partners Global..
2024/2/2720:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
2024/2/2320:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
2024/2/2106:14EDGAR2Form 8-K - Current report
2024/2/2020:45BWFDA Grants Priority Review to Merck's Application for..
2024/2/1606:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1606:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1506:40EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1506:30EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1506:24EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1406:50EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1406:48EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1306:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1221:05PRNCAHealth Canada Approves KEYTRUDA® in combination with..
2024/2/1006:06EDGAR2Form 144 - Report of proposed sale of securities
2024/2/0906:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0821:00PRNCAMERCK CANADA ANNONCE UNE COLLABORATION AVEC L'INSTITUT..
2024/2/0806:09EDGAR2Form 144 - Report of proposed sale of securities
2024/2/0606:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0520:33PRNUSElanco Announces Sale of Aqua Business for $1.3 Billion
2024/2/0306:35EDGAR2Form 144 - Report of proposed sale of securities
2024/2/0306:09EDGAR2Form 144 - Report of proposed sale of securities
2024/2/0306:08EDGAR2Form 144 - Report of proposed sale of securities
2024/2/0306:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0306:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0120:39EDGAR2Form 8-K - Current report
2024/2/0120:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
2024/1/2800:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
2024/1/2701:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..

最近閲覧した銘柄

Delayed Upgrade Clock